Incentives To PBMs For "Preferred" Drug Status May Be DoJ Lawsuit Target

The Department of Justice is investigating bad faith formulary decisions by pharmacy benefit management companies and lawsuits may follow, DoJ Civil Division Chief James Sheehan said at a Center for Business Intelligence conference on Pricing, Reimbursement & Formulary Management July 29 in Atlantic City.